Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab, Gemcitabine, and Docetaxel in Advanced NSCLC
NCT00193453Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Jul 2005
- Primary completion
- Feb 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of KL-140 in non-small cell lung cancer (NSCLC), sponsored by SCRI Development Innovations. Primary endpoint: Overall Clinical Response Rate at 18 months. Started Jul 2005; status: completed.
02
Drugs
KL-140
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00193453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193453.